TrialFind
Search
About
Saved trials
Back to results
Completed
Phase 1
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
NCT00291473
What is this trial?
Generating plain-language summary...
Am I eligible?
Generating eligibility summary...
What's involved?
Summarizing study design...
Where and how to apply
Primary location
Mie University Hospital
Tsu, Mie-ken, Japan
View on ClinicalTrials.gov
Official details
Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers — TrialFind